As shown in Figure 1A, based on the cIMPACT update 3, IDH-wild type gliomas could be divided into three groups: Group A diffuse astrocytic gliomas without TERT promoter mutation, EGFR amplification, and combined 7 + /10−, WHO grade II/III; Group B, diffuse astrocytic gliomas with any of TERT promoter mutation, EGFR amplification, or combined 7 + /10−, WHO grade IV (simplified as IDH-wild type WHO grade IV gliomas with molecular feature of GBM); and Group C, GBM, WHO grade IV. Here, EGFR is linked to central nervous system cancer.